Point72 Asset Management
BCYC

Point72 Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Point72 Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$636K Buy
149,936
+19,514
+15% +$89.5K ﹤0.01% 3064
2026
Q1 		$605K Buy
130,422
+53,643
+70% +$307K ﹤0.01% 3042
2025
Q4 		$544K Sell
76,779
-354,121
-82% -$2.61M ﹤0.01% 3193
2025
Q3 		$3.34M Sell
430,900
-1,341,700
-76% -$10.1M 0.01% 1232
2025
Q2 		$12.3M Sell
1,772,600
-1,919,469
-52% -$15.3M 0.02% 653
2025
Q1 		$31.3M Sell
3,692,069
-862,831
-19% -$10.2M 0.07% 324
2024
Q4 		$63.8M Buy
4,554,900
+3,655,101
+406% +$78.3M 0.14% 166
2024
Q3 		$20.4M Buy
899,799
+841,299
+1,438% +$19.4M 0.05% 416
2024
Q2 		$1.18M Sell
58,500
-284,094
-83% -$6.42M ﹤0.01% 1228
2024
Q1 		$8.53M Buy
342,594
+116,699
+52% +$2.48M 0.02% 772
2023
Q4 		$4.08M Sell
225,895
-1,073,605
-83% -$17.8M 0.01% 997
2023
Q3 		$26.1M Buy
1,299,500
+821,500
+172% +$18.8M 0.08% 332
2023
Q2 		$12.2M Sell
478,000
-324,400
-40% -$7.53M 0.04% 530
2023
Q1 		$17.1M Sell
802,400
-205,578
-20% -$5.16M 0.05% 402
2022
Q4 		$29.8M Sell
1,007,978
-247,440
-20% -$6.64M 0.1% 246
2022
Q3 		$29.2M Sell
1,255,418
-189,582
-13% -$4.51M 0.12% 231
2022
Q2 		$24.2M Sell
1,445,000
-174,802
-11% -$3.69M 0.1% 267
2022
Q1 		$71.1M Buy
1,619,802
+46,979
+3% +$2.19M 0.28% 89
2021
Q4 		$95.7M Sell
1,572,823
-42,269
-3% -$2.33M 0.38% 47
2021
Q3 		$67.2M Sell
1,615,092
-190,843
-11% -$6.67M 0.3% 64
2021
Q2 		$54.8M Buy
1,805,935
+228,442
+14% +$6.9M 0.25% 102
2021
Q1 		$47.1M Buy
1,577,493
+139,917
+10% +$3.61M 0.22% 117
2020
Q4 		$25.8M Buy
1,437,576
+74,425
+5% +$1.44M 0.13% 219
2020
Q3 		$26M Buy
1,363,151
+962,652
+240% +$17M 0.13% 213
2020
Q2 		$6.3M Hold
400,499
– – 0.04% 440
2020
Q1 		$5.47M Buy
400,499
+18,000
+5% +$229K 0.04% 371
2019
Q4 		$3.61M Buy
+382,499
New +$3.47M 0.02% 538

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Point72 Asset Management's BCYC Position: Q2 2026 in Review

Point72 Asset Management increased its Bicycle Therapeutics (BCYC) stake by 15% in Q2 2026, buying an estimated $89.5K and bringing the position to 149,936 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #3064.

Point72 Asset Management first reported a position in BCYC in Q4 2019 and has held it in 27 quarters since. The position peaked at $95.7M in Q4 2021. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • Point72 Asset Management held 149,936 shares of Bicycle Therapeutics worth $636K as of Q2 2026.
  • Point72 Asset Management bought 19,514 Bicycle Therapeutics shares in Q2 2026, an estimated $89.5K.
  • Bicycle Therapeutics made up ﹤0.01% of Point72 Asset Management's portfolio in Q2 2026, its #3064 holding.
  • Point72 Asset Management first reported a position in Bicycle Therapeutics in Q4 2019 and has held it in 27 quarters since.
  • Point72 Asset Management's Bicycle Therapeutics position peaked at $95.7M in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.